Propranolol: long-term treatment in narcolepsy-cataplexy. 1985

K Meier-Ewert, and K Matsubayashi, and L Benter

Forty-eight sequential narcoleptic patients were treated with propranolol (80-240 mg/day) for an average period of 18.4 months. Initially all patients received single drug therapy; after 10 days or longer, however, 50% of patients also received tricyclics or stimulants because propranolol alone did not sufficiently suppress the narcoleptic symptoms. Fifty percent of patients judged the initial effectiveness of propranolol on daytime sleepiness to be good to very good; in these patients the effects seemed comparable to that of pemoline. Within 6 months, however, the effectiveness started to decrease, and after 26 months only 8% (2 out of 24) of those patients taking the single drug were satisfied with propranolol therapy alone. Side effects included disturbed night sleep, decreased blood pressure, increased lethargy, allergic skin rash, and asthma; 58% of the patients dropped out of the study after 26 months. Vigilance tests during the first 4 months (16 patients) showed significant improvements in all test criteria, including a shorter reaction time. All-night polygraphic electroencephalogram recordings of 14 patients on the eighth and ninth day of medication showed that average total sleep time decreased by 5.7%, but other sleep characteristics did not change significantly.

UI MeSH Term Description Entries
D008134 Long-Term Care Care over an extended period, usually for a chronic condition or disability, requiring periodic, intermittent, or continuous care. Care, Long-Term,Long Term Care
D009290 Narcolepsy A condition characterized by recurrent episodes of daytime somnolence and lapses in consciousness (microsomnias) that may be associated with automatic behaviors and AMNESIA. CATAPLEXY; SLEEP PARALYSIS, and hypnagogic HALLUCINATIONS frequently accompany narcolepsy. The pathophysiology of this disorder includes sleep-onset rapid eye movement (REM) sleep, which normally follows stage III or IV sleep. (From Neurology 1998 Feb;50(2 Suppl 1):S2-S7) Gelineau Syndrome,Narcolepsy-Cataplexy Syndrome,Paroxysmal Sleep,Gelineau's Syndrome,Narcoleptic Syndrome,Gelineau's Syndromes,Gelineaus Syndrome,Narcolepsy Cataplexy Syndrome,Narcolepsy-Cataplexy Syndromes,Narcoleptic Syndromes,Sleep, Paroxysmal,Syndrome, Gelineau,Syndrome, Gelineau's,Syndrome, Narcolepsy-Cataplexy,Syndrome, Narcoleptic,Syndromes, Gelineau's,Syndromes, Narcolepsy-Cataplexy,Syndromes, Narcoleptic
D011433 Propranolol A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. Dexpropranolol,AY-20694,Anaprilin,Anapriline,Avlocardyl,Betadren,Dociton,Inderal,Obsidan,Obzidan,Propanolol,Propranolol Hydrochloride,Rexigen,AY 20694,AY20694,Hydrochloride, Propranolol
D002385 Cataplexy A condition characterized by transient weakness or paralysis of somatic musculature triggered by an emotional stimulus or physical exertion. Cataplexy is frequently associated with NARCOLEPSY. During a cataplectic attack, there is a marked reduction in muscle tone similar to the normal physiologic hypotonia that accompanies rapid eye movement sleep (SLEEP, REM). (From Adams et al., Principles of Neurology, 6th ed, p396) Henneberg Syndrome,Status Cataplexicus,Tonelessness Syndrome,Cataleptic Attacks,Attack, Cataleptic,Attacks, Cataleptic,Cataleptic Attack,Syndrome, Henneberg,Syndrome, Tonelessness,Syndromes, Tonelessness,Tonelessness Syndromes
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004569 Electroencephalography Recording of electric currents developed in the brain by means of electrodes applied to the scalp, to the surface of the brain, or placed within the substance of the brain. EEG,Electroencephalogram,Electroencephalograms
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001143 Arousal Cortical vigilance or readiness of tone, presumed to be in response to sensory stimulation via the reticular activating system. Vigilance, Cortical,Arousals,Cortical Vigilance
D001288 Attention Focusing on certain aspects of current experience to the exclusion of others. It is the act of heeding or taking notice or concentrating. Focus of Attention,Selective Attention,Social Attention,Attention Focus,Attention, Selective,Attention, Social,Selective Attentions
D012894 Sleep Stages Periods of sleep manifested by changes in EEG activity and certain behavioral correlates; they formerly included Stage 1: sleep onset, drowsy sleep; Stage 2: light sleep; Stages 3 and 4: delta sleep, light sleep, deep sleep, telencephalic sleep. In 2007, sleep stages were redefined by The American Academy of Sleep Medicine (AASM) as: N1-N2 (sleep onset - light sleep), N3 (SLOW-WAVE SLEEP), and REM SLEEP. N1-Sleep,N2-Sleep,NREM Stage 1,NREM Stage 2,N1 Sleep,N2 Sleep,Sleep Stage,Stage, Sleep,Stages, Sleep

Related Publications

K Meier-Ewert, and K Matsubayashi, and L Benter
March 2004, Sleep medicine,
K Meier-Ewert, and K Matsubayashi, and L Benter
March 2007, Lancet (London, England),
K Meier-Ewert, and K Matsubayashi, and L Benter
March 2007, Lancet (London, England),
K Meier-Ewert, and K Matsubayashi, and L Benter
January 1989, Schweizer Archiv fur Neurologie und Psychiatrie (Zurich, Switzerland : 1985),
K Meier-Ewert, and K Matsubayashi, and L Benter
August 2002, Revue medicale de Liege,
K Meier-Ewert, and K Matsubayashi, and L Benter
January 1946, Acta clinica Belgica,
K Meier-Ewert, and K Matsubayashi, and L Benter
April 1981, Drug intelligence & clinical pharmacy,
K Meier-Ewert, and K Matsubayashi, and L Benter
July 1985, Comprehensive therapy,
K Meier-Ewert, and K Matsubayashi, and L Benter
January 2010, Neuro endocrinology letters,
K Meier-Ewert, and K Matsubayashi, and L Benter
December 2004, The American journal of psychiatry,
Copied contents to your clipboard!